secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001628280-26-029125
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance
--------------------------------------------------------------------------------

- Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
- Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.
- Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.
- Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.
- Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/irmd-20260501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-029125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer